Loss of nuclear p27 expression and its prognostic role in relation to cyclin E and p53 mutation in gastroenteropancreatic neuroendocrine tumors

Clinical Cancer Research

Volumn 14, Issue 22, 2008, Pages 7378-7384

  Grabowski, Patricia ^a   Schrader, Jörg ^b   Wagner, Julia ^b   Hörsch, Dieter ^b   Arnold, Rudolf ^b   Arnold, Christian N ^c   Georgieva, Inna ^a   Stein, Harald ^a   Zeitz, Martin ^a   Daniel, Peter T ^a   Sturm, Isrid ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; INTERFERON; PROTEIN P27; PROTEIN P53; SMALL INTERFERING RNA; SOMATOSTATIN; CCNE1 PROTEIN, HUMAN; ONCOPROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CYCLE; CONTROLLED STUDY; ENDOCRINE TUMOR; FEMALE; FOLLOW UP; GASTROINTESTINAL TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUTATIONAL ANALYSIS; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; WORLD HEALTH ORGANIZATION; ANIMAL; BIOSYNTHESIS; CELL NUCLEUS; CLASSIFICATION; DIGESTIVE SYSTEM TUMOR; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; POLYMERASE CHAIN REACTION; RAT; SINGLE STRAND CONFORMATION POLYMORPHISM; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BLOTTING, WESTERN; CELL NUCLEUS; CYCLIN E; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DIGESTIVE SYSTEM NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MUTATION; NEUROENDOCRINE TUMORS; ONCOGENE PROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; RATS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 58149359319     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0698     Document Type: Article

References (29)

1. Williams ED, Sandler M. The classification of carcinoid tumours. Lancet 1963;7275:238-9.
2. Solcia E, Klöppel G, Sobin LH. Histological typing of endocrine tumours. 2nd ed. Berlin: Springer; 2000.
3. Perren A, Anlauf M, Komminoth P. Molecular profiles of gastroenteropancreatic endocrine tumors. Virchows Arch 2007;451:S39-46.
4. Grabowski P, Sutter AP, Scherübl H. Molekulare Regulation neuroendokriner Tumoren des Gastorintestinaltraktes. In: Ganten D, Ruckpaul K, editors. Berlin: Springer-Verlag, Deutschland; 2006. p. 291-308.
5. Güner D, Sturm I, Hemmati P, et al. Multigene analysis of Rb pathway and apoptosis control in esophageal squamous cell carcinoma identifies patients with good prognosis. Int J Cancer 2003;103:445-54.
6. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80:293-9.
7. Sturm I, Köhne CH, Wolff G, et al. Analysis of the p53/ BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol 1999;17:1364-74.
8. Schelwies K, Sturm I, Grabowski P, et al. Analysis of p53/BAX in primary colorectal carcinoma: low BAX protein expression is a negative prognostic factor in UICC stage III tumors. Int J Cancer 2002;99:589-96.
9. Rau B, Sturm I, Lage H, et al. Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Oncol 2003;21:3391-401.
10. Sturm I, Rau B, Schlag PM, et al. Genetic dissection of apoptosis and cell cycle control in response of colorectal cancer treated with preoperative radiochemotherapy. BMC Cancer 2006;6:124-33.
11. Grabowski P, Griss S, Arnold CN, et al. Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease. Neuroendocrinology 2005;81:1-9.
12. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003;22:8581-9.
13. Moyana TN, Xiang J, Senthilselvan A, Kulaga A. The spectrum of neuroendocrine differentiation among gastrointestinal carcinoids: importance of histologic grading, MIB-1, p53, and bcl-2 immunoreactivity. Arch Pathol Lab Med 2000;124:570-6.
14. Canavese G, Azzoni C, Pizzi S, et al. p27: a potential main inhibitor of cell proliferation in digestive endocrine tumors but not a marker of benign behavior. Hum Pathol 2001;32:1094-101.
15. Loda M, Cukor B, Tam SW, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3:231-4.
16. Yasui W, Kuniyasu H, Yokozaki H, Semba S, Shimamoto F, Tahara E. Expression of cyclin E in colorectal adenomas and adenocarcinomas: correlation with expression of Ki-67 antigen and p53 protein. Virchows Arch 1996;429:13-9.
17. Hommura F, Dosaka-Akita H, Mishina T, et al. Prognostic significance of p27KIP1 protein and Ki-67 growth fraction in non-small cell lung cancers. Clin Cancer Res 2000;6:4073-81.
18. Porter PL, Malone KE, Heagerty PJ, et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997;3:222-5.
19. Sui L, Dong Y, Ohno M, et al. Implication of malignancy and prognosis of p27(kip1), cyclin E, and Cdk2 expression in epithelial ovarian tumors. Gynecol Oncol 2001;83:56-63.
20. Porter PL, Barlow WE, Yeh IT, et al. p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy. J Natl Cancer Inst 2006;98:1723-31.
21. Span PN, Tjan-Heijnen VC, Manders P, Beex LV, Sweep CG. Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer. Oncogene 2003;22:4898-904.
22. Span PN, de Mulder PH, Sweep FC. Re: p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy. J Natl Cancer Inst 2007;99:738.
23. Akli S, Zheng PJ, Multani AS, et al. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 2004;64:3198-208.
24. Doganavsargil B, Sarsik B, Kirdok FS, Musoglu A, Tuncyurek M. p21 and p27 immunoexpression in gastric well differentiated endocrine tumors (ECL-cell carcinoids). World J Gastroenterol 2006;12:6280-4.
25. Vortmeyer AO, Lubensky IA, Merino MJ, et al. Concordance of genetic alterations in poorly differentiated colorectal neuroendocrine carcinomas and associated adenocarcinomas. J Natl Cancer Inst 1997;89:1448-53.
26. Cheng JY, Sheu LF, Meng CL, Lin JC. Expression of p53 protein in colorectal carcinoids. Arch Surg 1996;131:67-70.
27. O'Dowd G, Gosney JR. Absence of overexpression of p53 protein by intestinal carcinoid tumours. J Pathol 1995;17:403-4.
28. Lohmann DR, Funk A, Niedermeyer HP, Haupel S, Hofler H. Identification of p53 gene mutations in gastrointestinal and pancreatic carcinoids by nonradioisotopic SSCA. Virchows Arch B Cell Pathol Incl Mol Pathol 1993;64:293-6.
29. Blain SW, Scher HI, Cordon-Cardo C, Koff A. p27 as a target for cancer therapeutics. Cancer Cell 2003;3:111-5.